[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100084247":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":16,"centralContacts":7,"locations":22,"responsibleParty":7,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":7,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":7,"targetDuration":7,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Heidelberg University","OTHER",null,[9,12,14],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Methylene blue",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Artesunate",{"type":10,"name":15,"description":7,"armGroupLabels":7,"otherNames":7},"Amodiaquine",[17,20],{"name":18,"affiliation":5,"role":19},"Olaf Mueller, MD, MPH","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":5,"role":19},"Peter Meissner, MD, MSc Trop Paed",[23],{"facility":24,"status":7,"city":25,"state":7,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":7},"Nouna District Hospital","Nouna","Burkina Faso","BF",{"type":29,"coordinates":30},"Point",[31,32],-3.86305,12.72939,{"lat":32,"lon":31},"100084247","phase-2-safety-and-efficacy-of-methylene-blue-combined-with-artesunate-or-amodiaquine-for-malaria-treatment-in-children-of-burkina-faso-a-pilot-study-100084247",false,"NCT00354380","Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study","Inclusion criteria:\n\n* 6-10 year old children\n* Ability to swallow tablets\n* Uncomplicated malaria caused by P. falciparum\n* Asexual parasites ≥ 2000\u002Fµl and \\\u003C 200000\u002Fµl\n* Axillary temperature ≥ 37.5°C\n* Burkinabe nationality\n* Informed consent\n\nExclusion Criteria:\n\n* Complicated or severe malaria\n* Any apparent significant disease\n* Anaemia (haematocrit \\\u003C 21%)\n* Treated in the same trial before\n* Antimalarial treatment prior to inclusion (last three days), except children having been treated with chloroquine","ALL","6 Years","10 Years","INTERVENTIONAL",[45],"PHASE2","The primary objective of this trial is to study the safety of the combination methylene blue (MB)-artesunate (AS) and MB-amodiaquine (AQ) in treating malaria among children compared to the safety of an AS-AQ regimen. The secondary objective is to investigate the efficacy of MB-AS and MB-AQ.",[48],"Malaria",[48,50,51,13,15],"Africa","Methalyne-blue","COMPLETED","2006-10-23",{"date":55,"type":56},"2006-10-24","ESTIMATED",{"date":58,"type":7},"2006-09",{"date":60,"type":7},"2006-11",{"name":5,"class":6},1]